Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.61 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.61 |
| ▸ | TAF1 | P21675 | 2/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.61 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.61 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.61 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 17/20 | 0.56 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.56 |
| ▸ | BPTF | Q12830 | 1/20 | 0.56 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658128 | 0.97 | BRD9 (0.57) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL16658125 | 0.89 | BRD4 (0.65) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL16658130 | 0.88 | BRD4 (0.66) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL16658126 | 0.86 | BRD4 (0.67) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL16658062 | 0.86 | BRD4 (0.67) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL16658115 | 0.85 | BRD4 (0.67) | BRD9BRD7TAF1TGFBR1ACVR1 | |
| SCHEMBL16657996 | 0.84 | BRD4 (0.64) | BRD9BRD7BRD4 | |
| SCHEMBL16658152 | 0.84 | BRD4 (0.77) | BRD4 | |
| SCHEMBL16658147 | 0.84 | BRD4 (0.77) | BRD4 | |
| SCHEMBL16658132 | 0.84 | BRD4 (0.68) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3290407-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | BRD9 19/4885BRD7 14/4885TAF1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.